HER-2/neu in bladder carcinoma

Research output: Contribution to journalArticle

Abstract

A total of 66 bladder cancer patients were studied to verify possible relationships between HER-2/neu alterations and pathological characteristics, and to define a poor prognosis patient subgroup with respect to time to recurrence, time to progression and survival. Tumor and healthy tissue specimens were analyzed for HER-2/neu DNA amplification and protein overexpression by Southern and Western blot techniques and evaluated statistically. 13% of cases were amplified and 39% were overexpressed. HER-2/ neu alterations were not significantly associated with pathological staging or tumor grading. Multifocal tumors had a higher percentage and overexpression with respect to monofocal tumors. Actuarial analyses did not show a significant statistical correlation between HER-2/neu amplification and overexpression and clinical outcome. Clinical evaluation of HER-2/neu status showed that this gene is not related to tumor relapse, progression or patient survival.

Original languageEnglish
Pages (from-to)957-961
Number of pages5
JournalInternational Journal of Oncology
Volume8
Issue number5
Publication statusPublished - 1996

Fingerprint

Urinary Bladder
Carcinoma
Neoplasms
Actuarial Analysis
Recurrence
Survival
Neoplasm Grading
Southern Blotting
Urinary Bladder Neoplasms
Western Blotting
DNA
Genes
Proteins

Keywords

  • Bladder carcinoma
  • HER-2/neu

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

HER-2/neu in bladder carcinoma. / Tommasi, Stefania.

In: International Journal of Oncology, Vol. 8, No. 5, 1996, p. 957-961.

Research output: Contribution to journalArticle

@article{940d2a9663a140d8800013fb4fa8b736,
title = "HER-2/neu in bladder carcinoma",
abstract = "A total of 66 bladder cancer patients were studied to verify possible relationships between HER-2/neu alterations and pathological characteristics, and to define a poor prognosis patient subgroup with respect to time to recurrence, time to progression and survival. Tumor and healthy tissue specimens were analyzed for HER-2/neu DNA amplification and protein overexpression by Southern and Western blot techniques and evaluated statistically. 13{\%} of cases were amplified and 39{\%} were overexpressed. HER-2/ neu alterations were not significantly associated with pathological staging or tumor grading. Multifocal tumors had a higher percentage and overexpression with respect to monofocal tumors. Actuarial analyses did not show a significant statistical correlation between HER-2/neu amplification and overexpression and clinical outcome. Clinical evaluation of HER-2/neu status showed that this gene is not related to tumor relapse, progression or patient survival.",
keywords = "Bladder carcinoma, HER-2/neu",
author = "Stefania Tommasi",
year = "1996",
language = "English",
volume = "8",
pages = "957--961",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - HER-2/neu in bladder carcinoma

AU - Tommasi, Stefania

PY - 1996

Y1 - 1996

N2 - A total of 66 bladder cancer patients were studied to verify possible relationships between HER-2/neu alterations and pathological characteristics, and to define a poor prognosis patient subgroup with respect to time to recurrence, time to progression and survival. Tumor and healthy tissue specimens were analyzed for HER-2/neu DNA amplification and protein overexpression by Southern and Western blot techniques and evaluated statistically. 13% of cases were amplified and 39% were overexpressed. HER-2/ neu alterations were not significantly associated with pathological staging or tumor grading. Multifocal tumors had a higher percentage and overexpression with respect to monofocal tumors. Actuarial analyses did not show a significant statistical correlation between HER-2/neu amplification and overexpression and clinical outcome. Clinical evaluation of HER-2/neu status showed that this gene is not related to tumor relapse, progression or patient survival.

AB - A total of 66 bladder cancer patients were studied to verify possible relationships between HER-2/neu alterations and pathological characteristics, and to define a poor prognosis patient subgroup with respect to time to recurrence, time to progression and survival. Tumor and healthy tissue specimens were analyzed for HER-2/neu DNA amplification and protein overexpression by Southern and Western blot techniques and evaluated statistically. 13% of cases were amplified and 39% were overexpressed. HER-2/ neu alterations were not significantly associated with pathological staging or tumor grading. Multifocal tumors had a higher percentage and overexpression with respect to monofocal tumors. Actuarial analyses did not show a significant statistical correlation between HER-2/neu amplification and overexpression and clinical outcome. Clinical evaluation of HER-2/neu status showed that this gene is not related to tumor relapse, progression or patient survival.

KW - Bladder carcinoma

KW - HER-2/neu

UR - http://www.scopus.com/inward/record.url?scp=0029949193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029949193&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0029949193

VL - 8

SP - 957

EP - 961

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 5

ER -